Development of a PAMAM Dendrimer for Sustained Release of Temozolomide against Experimental Murine Lymphoma: Assessment of Therapeutic Efficacy

2021 ◽  
Author(s):  
Ugir Hossain Sk ◽  
Sumit Kumar Hira ◽  
Abhinandan Rej ◽  
Debapriya RoyMahapatra ◽  
Partha Pratim Manna
Keyword(s):  
Sustained Release ◽  
Therapeutic Efficacy ◽  
Pamam Dendrimer ◽  
Murine Lymphoma

scholarly journals Design of Oral Sustained-Release Pellets by Modeling and Simulation Approach to Improve Compliance for Repurposing Sobrerol

Pharmaceutics ◽  
2022 ◽  
Vol 14 (1) ◽  
pp. 167
Author(s):  
Chu-Hsun Lu ◽  
Yu-Feng Huang ◽  
I-Ming Chu
Keyword(s):  
Sustained Release ◽  
Modeling And Simulation ◽  
Therapeutic Efficacy ◽  
Drug Product ◽  
Release Kinetics ◽  
Gastrointestinal Transit ◽  
Simulation Approach ◽  
Duration Of Action ◽  
Minimum Effective Concentration ◽  
Daily Dose

Sobrerol, an oral mucolytic agent, in a recent study showed promise for treating multiple sclerosis. A human equivalent dose of 486 mg of sobrerol administered thrice daily (i.e., 1459 mg of daily dose) demonstrated the highest therapeutic efficacy for repurposing use, which also points out the poor compliance of administration. In this study, oral sustained-release pellets of sobrerol were successfully developed with evaluated manufacturing conditions and drug release kinetics. For design of the target drug product, we used a modeling and simulation approach to establish a predictive model of oral pharmacokinetic profile, by exploring the characteristics and correlations corresponding to the pharmacokinetics and pharmacodynamics of sobrerol, such as absorption lag time (0.18 h), time-scaling in vitro–in vivo correlation (tin-vitro = 0.494 tin-vivo − 0.0904), gastrointestinal transit time (8 h), minimum effective concentration (1.61 μg/mL), and duration of action (12.8 h). Results showed that the frequency of administration and the daily dose remarkably reduced by 33.3% (i.e., from thrice to twice daily) and 22.8%, respectively, which indicates that this prototype approach can be adopted for rapidly developing a modified-release dosage form of sobrerol, with improvement of compliance of administration and therapeutic efficacy.

scholarly journals Therapeutic Efficacy of Poly(dl-Lactide-Co-Glycolide)-Encapsulated Antitubercular Drugs against Mycobacterium tuberculosis Infection Induced in Mice

2001 ◽  
Vol 45 (1) ◽  
pp. 363-366 ◽  
Author(s):  
Manisha Dutt ◽  
G. K. Khuller
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Single Dose ◽  
Sustained Release ◽  
Therapeutic Efficacy ◽  
Tuberculosis Infection ◽  
Daily Administration ◽  
Single Shot ◽  
Mycobacterium Tuberculosis Infection ◽  
Antitubercular Drugs ◽  
Improve Compliance

ABSTRACT Poly(dl-lactide-co-glycolide) (PLG) microparticles were developed as carriers for isoniazid and rifampin in order to improve compliance of tuberculous chemotherapy. Antitubercular drugs encapsulated in PLG polymers and injected in a single dose subcutaneously resulted in a sustained release (up to 6 weeks) of drugs in various organs of mice. Further, Mycobacterium tuberculosis H37Rv-infected animals given a single shot of chemotherapy in PLG microparticles exhibited a better or equivalent clearance of CFU in various organs compared to those given a daily administration of free drugs.

scholarly journals Formulation, characterization and evaluation of morusin loaded niosomes for potentiation of anticancer therapy

RSC Advances ◽  
2018 ◽  
Vol 8 (57) ◽  
pp. 32621-32636 ◽  
Author(s):  
Srishti Agarwal ◽  
M. Sheikh Mohamed ◽  
Sreejith Raveendran ◽  
Ankit K. Rochani ◽  
Toru Maekawa ◽  
...  
Keyword(s):  
Sustained Release ◽  
Cell Lines ◽  
Cancer Cell ◽  
Therapeutic Efficacy ◽  
Drug Loading ◽  
Anticancer Therapy ◽  
Cancer Cell Lines ◽  
High Drug ◽  
High Drug Loading

Highly cytocompatible morusin-loaded niosomes were synthesized showing high drug loading and encapsulation efficiencies with sustained release of the drug. Enhanced therapeutic efficacy was observed against 4 different cancer cell lines.

Ultrastructural changes in murine lymphoma cells exposed to ultraviolet-A radiation

1991 ◽  
Vol 49 ◽  
pp. 104-105
Author(s):  
Delma P. Thomas ◽  
Dianne E. Godar
Keyword(s):  
Medical Devices ◽  
Blood Cells ◽  
White Blood Cells ◽  
Consumer Products ◽  
Ultrastructural Changes ◽  
Ultraviolet A ◽  
Uv Spectrum ◽  
Lymphoma Cells ◽  
Murine Lymphoma ◽  
Transmission Electron

Ultraviolet radiation (UVR) from all three waveband regions of the UV spectrum, UVA (320-400 nm), UVB (290-320 nm), and UVC (200-290 nm), can be emitted by some medical devices and consumer products. Sunlamps can expose the blood to a considerable amount of UVR, particularly UVA and/or UVB. The percent transmission of each waveband through the epidermis to the dermis, which contains blood, increases in the order of increasing wavelength: UVC (10%) < UVB (20%) < UVA (30%). To investigate the effects of UVR on white blood cells, we chose transmission electron microscopy to examine the ultrastructure changes in L5178Y-R murine lymphoma cells.

1558: Local Injection of Sustained-Release Antiandrogen Formulation into a Target Prostatic Site: An Experimental Study

2007 ◽  
Vol 177 (4S) ◽  
pp. 515-515
Author(s):  
Nobuyuki Goya ◽  
Kotara Gotanda ◽  
Yasuko Tomizawa ◽  
Hiroshi Toma
Keyword(s):  
Experimental Study ◽  
Sustained Release ◽  
Local Injection
Sign in / Sign up

Export Citation Format

Share Document